LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Composition of the Gut Microbiome Differentiates Normal Individuals from Those with Precancerous Polyps or Invasive Colorectal Cancer

By LabMedica International staff writers
Posted on 18 Aug 2014
Print article
A recent paper described how analysis of the gut microbiome could be used to differentiate healthy individuals from those with precancerous adenomatous polyps and those with invasive colorectal cancer.

Investigators at the University of Michigan (Ann Arbor, USA) characterized the gut microbiome in 90 patients from three clinical groups representing the stages of colorectal cancer development: healthy, adenoma, and carcinoma (30 patients representing each group). To identify the bacteria present in each individual's gut microbiome, the investigators sequenced the V4 region of the 16S rRNA gene.

They reported that analysis of the gut microbiome from stool samples revealed both an enrichment and depletion of several bacterial populations associated with adenomas and carcinomas. Combined with known clinical risk factors of colorectal cancer such as BMI (body mass index), age, and race; data from the gut microbiome significantly improved the ability to differentiate between healthy, adenoma, and carcinoma clinical groups relative to risk factors alone.

"We found that the composition of the gut microbiome allowed us to identify who in our study had precancerous adenomatous polyps and who had invasive colorectal cancer," said senior author Dr. Patrick D. Schloss, associate professor of microbiology and immunology at the University of Michigan. "If our results are confirmed in larger groups of people, adding gut microbiome analysis to other fecal tests may provide an improved, noninvasive way to screen for colorectal cancer."

"Our data show that gut microbiome analysis has the potential to be a new tool to noninvasively screen for colorectal cancer," said Dr, Schloss. "We do not think that this would ever replace other colorectal cancer screening approaches, rather we see it as complementary."

The gut microbiome study was published in the August 7, 2014, online edition of the journal Cancer Prevention Research.

Related Links:
University of Michigan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more